Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
|
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [21] The Serological Response Of Asthmatics To The 23-Valent Pneumococcal Polysaccharide Vaccine (ppsv23)
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [22] Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children
    Sigurdardottir, Sigurveig Th.
    Center, Kimberly J.
    Davidsdottir, Katrin
    Arason, Vilhjalmur A.
    Hjalmarsson, Bjorn
    Elisdottir, Ragnheidur
    Ingolfsdottir, Gunnhildur
    Northington, Robert
    Scott, Daniel A.
    Jonsdottir, Ingileif
    VACCINE, 2014, 32 (03) : 417 - 424
  • [23] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [24] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
  • [25] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [26] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [27] IMMUNOGENICITY AND SAFETY OF A 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN HEALTHY-CHILDREN AND IN CHILDREN AT INCREASED RISK OF PNEUMOCOCCAL INFECTION
    LEE, HJ
    KANG, JH
    HENRICHSEN, J
    KONRADSEN, HB
    JANG, SH
    SHIN, HY
    AHN, HS
    CHOI, Y
    HESSEL, L
    NAM, SW
    VACCINE, 1995, 13 (16) : 1533 - 1538
  • [28] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [29] Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017
    Shimbashi, Reiko
    Suzuki, Motoi
    Chang, Bin
    Watanabe, Hiroshi
    Tanabe, Yoshinari
    Kuronuma, Koji
    Oshima, Kengo
    Maruyama, Takaya
    Takeda, Hiroaki
    Kasahara, Kei
    Fujita, Jiro
    Nishi, Junichiro
    Kubota, Tetsuya
    Tanaka-Taya, Keiko
    Matsui, Tamano
    Sunagawa, Tomimasa
    Oishi, Kazunori
    EMERGING INFECTIOUS DISEASES, 2020, 26 (10) : 2378 - 2386
  • [30] Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China
    Zhao, Daijun
    Tobe, Ruoyan Gai
    Cui, Min
    He, Jinchun
    Wu, Bin
    VACCINE, 2016, 34 (50) : 6158 - 6165
12345